HLB Life Science Co. Ltd (067630) — Cash Flow-to-Debt Ratio
HLB Life Science Co. Ltd (067630) has a Cash Flow-to-Debt Ratio of -0.02x as of September 2025, meaning its operating cash flow of ₩-4.30 Billion could theoretically repay 0% of its total liabilities (₩173.00 Billion) in one year. See HLB Life Science Co. Ltd (067630) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
HLB Life Science Co. Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for HLB Life Science Co. Ltd across 13 annual periods. For the full cash flow conversion analysis, see 067630 cash flow conversion.
Annual Cash Flow-to-Debt Ratio for HLB Life Science Co. Ltd (2012–2024)
Year-by-year debt coverage analysis for HLB Life Science Co. Ltd. Check HLB Life Science Co. Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | ₩-32.01 Billion | ₩140.19 Billion | ▼ -338.3% |
| 2023 | -0.05x | ₩-10.02 Billion | ₩192.29 Billion | ▲ +69.0% |
| 2022 | -0.17x | ₩-29.74 Billion | ₩177.07 Billion | ▲ +70.6% |
| 2021 | -0.57x | ₩-14.08 Billion | ₩24.61 Billion | ▼ -1239.3% |
| 2020 | 0.05x | ₩2.01 Billion | ₩40.02 Billion | ▲ +128.8% |
| 2019 | -0.17x | ₩-12.39 Billion | ₩71.11 Billion | ▼ -163.0% |
| 2018 | -0.07x | ₩-11.07 Billion | ₩167.17 Billion | ▼ -913.0% |
| 2017 | -0.01x | ₩-302.04 Million | ₩46.19 Billion | ▲ +84.2% |
| 2016 | -0.04x | ₩-2.27 Billion | ₩54.99 Billion | ▲ +84.0% |
| 2015 | -0.26x | ₩-4.34 Billion | ₩16.80 Billion | ▼ -149.4% |
| 2014 | 0.52x | ₩10.43 Billion | ₩19.95 Billion | ▲ +559.4% |
| 2013 | 0.08x | ₩2.95 Billion | ₩37.19 Billion | ▼ -78.0% |
| 2012 | 0.36x | ₩13.97 Billion | ₩38.83 Billion | — |